A generic alternative indicated for Cholesterol. Treatment promotes the breakdown of triglycerides and total lipids circulating within the bloodstream.
Formulated to address elevated triglycerides to alleviate the risk of pancreatitis and support cardiovascular health by mitigating fatty acid buildup in the bloodstream.
Mechanism of Action
Fenofibrate activates a specific receptor (PPAR-alpha) that increases the breakdown of fat in the blood. It lowers triglycerides and improves the levels of 'good' HDL cholesterol by changing how the liver processes lipids.
Route of Administration
Oral
Onset Time
Steady state in 1–2 weeks
Duration
24 hours
Contraindications
Severe kidney disease, Active liver disease, Gallbladder disease, Breastfeeding, Hypersensitivity to fenofibrate
Severe Adverse Events
Severe muscle breakdown (rhabdomyolysis), Liver toxicity, Pancreatitis, Gallstones, Severe allergic reactions, Pulmonary embolism
Information for Fenofibrate is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
